Akari Therapeutics Plc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income
Condensed Consolidated Statements of Operations
and Comprehensive (Loss) Income
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| (In thousands, except share and per share amounts) | 2024 | 2023 |
| Operating expenses: | ||
| Research and development | $2,279 | $1,731 |
| General and administrative | 3,710 | 2,863 |
| Loss from operations | (5,989) | (4,594) |
| Other income (expense): | ||
| Interest income | 2 | 30 |
| Change in fair value of warrant liability | 649 | 5,587 |
| Foreign currency exchange loss, net | (226) | (11) |
| Other expense, net | (2) | (11) |
| Total other income (expense), net | 423 | 5,595 |
| Net (loss) income | $(5,566) | $1,001 |
| Net (loss) income per share –– basic and diluted | $(0.00) | $0.00 |
| Weighted-average number of ordinary shares used in computing net (loss) income per share | ||
| — Basic | 13,453,147,979 | 7,474,546,753 |
| — Diluted | 13,453,147,979 | 7,573,542,457 |
| Comprehensive (loss) income: | ||
| Net (loss) income | $(5,566) | $1,001 |
| Other comprehensive income, net of tax: | ||
| Foreign currency translation adjustment | 279 | 2 |
| Total other comprehensive income, net of tax | 279 | 2 |
| Total comprehensive (loss) income | $(5,287) | $1,003 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.